Background: Somatostatin analogs (SSAs) binding to and activating somatostatin receptors (SSTRs) have been extensively used for the treatment of neuroendocrine tumors (NETs). The currently approved synthetic SSAs have high affinity for SSTR2 (octreotide/lanreotide) or for SSTR2 and SSTR5 (pasireotide). These agents have shown symptom control and antiproliferative effects in subsets of NET patients and this was associated with the expression of the targeted SSTRs. Pancreatic NETs (Pan-NETs) are uncommon tumors with a propensity to metastasize. For unresectable advanced Pan-NETs expressing SSTRs, SSAs are the first-line medical therapy. Pan-NETs express mainly SSTR1, SSTR2, and SSTR3 and thus should respond to agonists targeting SSTR3. Summary: We evaluated the efficacy of ITF2984, a novel multireceptor agonist with specificity for SSTR3, against Pan-NET cells representative of well-differentiated, functioning tumors, and expressing high levels of SSTR3. The effect of ITF2984 on cell proliferation/viability and on its ability to promote apoptosis and suppress hormone secretion was evaluated in 2D and 3D organotypic culture systems. Pasireotide was tested in parallel for comparative purposes. Key Message: We found that ITF2984 is as effective as pasireotide at inhibiting both proliferation/viability and hormone secretion, as well as at inducing apoptosis of Pan-NET cells grown as both 2D monolayers and 3D spheroids. High-dose ITF2984 elicits structural alterations in Pan-NET 3D spheroids compatible with cell death more effectively than pasireotide. Altogether, ITF2984 may represent a useful alternative to pasireotide for the medical treatment of Pan-NETs and other tumors with elevated SSTR3 expression.

1.
Ehehalt
F
,
Saeger
HD
,
Schmidt
CM
,
Grützmann
R
.
Neuroendocrine tumors of the pancreas
.
Oncologist
.
2009
;
14
(
5
):
456
67
.
2.
Inzani
F
,
Petrone
G
,
Rindi
G
.
The new world health organization classification for pancreatic neuroendocrine neoplasia
.
Endocrinol Metab Clin North Am
.
2018
;
47
(
3
):
463
70
.
3.
Jensen
RT
,
Cadiot
G
,
Brandi
ML
,
de Herder
WW
,
Kaltsas
G
,
Komminoth
P
, et al
.
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes
.
Neuroendocrinology
.
2012
;
95
(
2
):
98
119
.
4.
Rindi
G
,
Mete
O
,
Uccella
S
,
Basturk
O
,
La Rosa
S
,
Brosens
LAA
, et al
.
Overview of the 2022 WHO classification of neuroendocrine neoplasms
.
Endocr Pathol
.
2022
;
33
(
1
):
115
54
.
5.
Botling
J
,
Lamarca
A
,
Bajic
D
,
Norlén
O
,
Lönngren
V
,
Kjaer
J
, et al
.
High-grade progression confers poor survival in pancreatic neuroendocrine tumors
.
Neuroendocrinology
.
2020
;
110
(
11–12
):
891
8
.
6.
Dasari
A
,
Shen
C
,
Halperin
D
,
Zhao
B
,
Zhou
S
,
Xu
Y
, et al
.
Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States
.
JAMA Oncol
.
2017
;
3
(
10
):
1335
42
.
7.
Rinke
A
,
Auernhammer
CJ
,
Bodei
L
,
Kidd
M
,
Krug
S
,
Lawlor
R
, et al
.
Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine
.
Gut
.
2021
;
70
(
9
):
1768
81
.
8.
Theodoropoulou
M
,
Stalla
GK
.
Somatostatin receptors: from signaling to clinical practice
.
Front Neuroendocrinol
.
2013
;
34
(
3
):
228
52
.
9.
Günther
T
,
Tulipano
G
,
Dournaud
P
,
Bousquet
C
,
Csaba
Z
,
Kreienkamp
HJ
, et al
.
International union of basic and clinical pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature
.
Pharmacol Rev
.
2018
;
70
(
4
):
763
835
.
10.
Pavel
M
,
Valle
JW
,
Eriksson
B
,
Rinke
A
,
Caplin
M
,
Chen
J
, et al
.
ENETS Consensus Guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy: biotherapy and novel targeted agents
.
Neuroendocrinology
.
2017
;
105
(
3
):
266
80
.
11.
Mazziotti
G
,
Mosca
A
,
Frara
S
,
Vitale
G
,
Giustina
A
.
Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects
.
Expert Opin Pharmacother
.
2017
;
18
(
16
):
1679
89
.
12.
Rinke
A
,
Müller
HH
,
Schade-Brittinger
C
,
Klose
KJ
,
Barth
P
,
Wied
M
, et al
.
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group
.
J Clin Oncol
.
2009
;
27
(
28
):
4656
63
.
13.
Caplin
ME
,
Pavel
M
,
Ćwikła
JB
,
Phan
AT
,
Raderer
M
,
Sedláčková
E
, et al
.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors
.
N Engl J Med
.
2014
;
371
(
3
):
224
33
.
14.
Plöckinger
U
,
Albrecht
S
,
Mawrin
C
,
Saeger
W
,
Buchfelder
M
,
Petersenn
S
, et al
.
Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas
.
J Clin Endocrinol Metab
.
2008
;
93
(
4
):
1203
10
.
15.
Papotti
M
,
Bongiovanni
M
,
Volante
M
,
Allìa
E
,
Landolfi
S
,
Helboe
L
, et al
.
Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis
.
Virchows Arch
.
2002
;
440
(
5
):
461
75
.
16.
Mohamed
A
,
Blanchard
M
,
Albertelli
M
,
Barbieri
F
,
Brue
T
,
Niccoli
P
, et al
.
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures
.
Endocr Relat Cancer
.
2014
;
21
(
5
):
691
704
.
17.
Shahbaz
M
,
Ruliang
F
,
Xu
Z
,
Benjia
L
,
Cong
W
,
Zhaobin
H
, et al
.
MRNA Expression of Somatostatin Receptor Subtypes SSTR-2, SSTR-3, and SSTR-5 and its SignimRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer. cance in Pancreatic Cancer
.
World J Surg Oncol
.
2015
;
13
:
46
,
18.
Kimura
N
,
Pilichowska
M
,
Date
F
,
Kimura
I
,
Schindler
M
.
Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors
.
Clin Cancer Res
.
1999
;
5
(
11
):
3483
7
.
19.
Yerci
O
,
Sehitoglu
I
,
Ugras
N
,
Cubukcu
E
,
Yuce
S
,
Bedir
R
, et al
.
Somatostatin receptor 2 and 5 expressions in gastroenteropancreatic neuroendocrine tumors in Turkey
.
Asian Pac J Cancer Prev
.
2015
;
16
(
10
):
4377
81
.
20.
Remes
SM
,
Leijon
HL
,
Vesterinen
TJ
,
Arola
JT
,
Haglund
CH
.
Immunohistochemical expression of somatostatin receptor subtypes in a panel of neuroendocrine neoplasias
.
J Histochem Cytochem
.
2019
;
67
(
10
):
735
43
.
21.
Reubi
JC
,
Waser
B
.
Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting
.
Eur J Nucl Med Mol Imaging
.
2003
;
30
(
5
):
781
93
.
22.
Bertherat
J
,
Tenenbaum
F
,
Perlemoine
K
,
Videau
C
,
Alberini
JL
,
Richard
B
, et al
.
Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study
.
J Clin Endocrinol Metab
.
2003
;
88
(
11
):
5353
60
.
23.
Bruns
C
,
Lewis
I
,
Briner
U
,
Meno-Tetang
G
,
Weckbecker
G
.
SOM230: a novel somatostatin peptidomimetic with broad Somatotropin Release Inhibiting Factor (SRIF) receptor binding and a unique antisecretory profile
.
Eur J Endocrinol
.
2002
;
146
(
5
):
707
16
.
24.
Schmid
HA
.
Pasireotide (SOM230): development, mechanism of action and potential applications
.
Mol Cell Endocrinol
.
2008
;
286
(
1–2
):
69
74
.
25.
Colao
A
,
Bronstein
MD
,
Freda
P
,
Gu
F
,
Shen
CC
,
Gadelha
M
, et al
.
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study
.
J Clin Endocrinol Metab
.
2014
;
99
(
3
):
791
9
.
26.
Lacroix
A
,
Gu
F
,
Gallardo
W
,
Pivonello
R
,
Yu
Y
,
Witek
P
, et al
.
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
.
Lancet Diabetes Endocrinol
.
2018
;
6
(
1
):
17
26
.
27.
Vitale
G
,
Dicitore
A
,
Sciammarella
C
,
Di Molfetta
S
,
Rubino
M
,
Faggiano
A
, et al
.
Pasireotide in the treatment of neuroendocrine tumors: a review of the literature
.
Endocr Relat Cancer
.
2018
;
25
(
6
):
R351
64
.
28.
Faggiano
A
.
Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story
.
J Endocrinol Invest
.
2024
;
47
(
1
):
35
46
.
29.
Wolin
EM
,
Jarzab
B
,
Eriksson
B
,
Walter
T
,
Toumpanakis
C
,
Morse
MA
, et al
.
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
.
Drug Des Devel Ther
.
2015
;
9
:
5075
86
.
30.
Cives
M
,
Kunz
PL
,
Morse
B
,
Coppola
D
,
Schell
MJ
,
Campos
T
, et al
.
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
.
Endocr Relat Cancer
.
2015
;
22
(
1
):
1
9
.
31.
Yao
JC
,
Chan
JA
,
Mita
AC
,
Kundu
MG
,
Hermosillo Reséndiz
K
,
Hu
K
, et al
.
Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
.
Onco Targets Ther
.
2017
;
10
:
3177
86
.
32.
Samson
SL
,
Gu
F
,
Feldt-Rasmussen
U
,
Zhang
S
,
Yu
Y
,
Witek
P
, et al
.
Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
.
Pituitary
.
2021
;
24
(
6
):
887
903
.
33.
Ferraù
F
,
Albani
A
,
Ciresi
A
,
Giordano
C
,
Cannavò
S
.
Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment
.
Front Endocrinol
.
2018
;
9
:
358
.
34.
Störmann
S
,
Meyhöfer
SM
,
Groener
JB
,
Faust
J
,
Schilbach
K
,
Seufert
J
, et al
.
Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts’ consensus statement
.
Front Endocrinol
.
2024
;
15
:
1348990
.
35.
Modena
D
,
Moras
ML
,
Sandrone
G
,
Stevenazzi
A
,
Vergani
B
,
Dasgupta
P
, et al
.
Identification of a novel SSTR3 full agonist for the treatment of nonfunctioning pituitary adenomas
.
Cancers
.
2023
;
15
(
13
):
3453
.
36.
Di Muro
G
,
Catalano
R
,
Treppiedi
D
,
Barbieri
AM
,
Mangili
F
,
Marra
G
, et al
.
The novel SSTR3 agonist ITF2984 exerts antimitotic and proapoptotic effects in human non-functioning pituitary neuroendocrine tumor (NF-PitNET) cells
.
Int J Mol Sci
.
2024
;
25
(
7
):
3606
.
37.
Benten
D
,
Behrang
Y
,
Unrau
L
,
Weissmann
V
,
Wolters-Eisfeld
G
,
Burdak-Rothkamm
S
, et al
.
Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model
.
Mol Cancer Res
.
2018
;
16
(
3
):
496
507
.
38.
Lv
D
,
Hu
Z
,
Lu
L
,
Lu
H
,
Xu
X
.
Three-dimensional cell culture: a powerful tool in tumor research and drug discovery
.
Oncol Lett
.
2017
;
14
(
6
):
6999
7010
.
39.
Hsieh
C
,
Chen
Y
,
Huang
S
,
Wang
H
,
Wu
M
.
The effect of primary cancer cell culture models on the results of drug chemosensitivity assays: the application of perfusion microbioreactor system as cell culture vessel
.
BioMed Res Int
.
2015
;
2015
:
470283
.
40.
Kapałczyńska
M
,
Kolenda
T
,
Przybyła
W
,
Zajączkowska
M
,
Teresiak
A
,
Filas
V
, et al
.
2D and 3D cell cultures: a comparison of different types of cancer cell cultures
.
Arch Med Sci
.
2018
;
14
(
4
):
910
9
.
41.
Guan
X
,
Huang
S
.
Advances in the application of 3D tumor models in precision oncology and drug screening
.
Front Bioeng Biotechnol
.
2022
;
10
:
1021966
.
42.
Florio
T
,
Morini
M
,
Villa
V
,
Arena
S
,
Corsaro
A
,
Thellung
S
, et al
.
Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities
.
Endocrinology
.
2003
;
144
(
4
):
1574
84
.
43.
Tower-Gilchrist
C
,
Styers
ML
,
Yoder
BK
,
Berbari
NF
,
Sztul
E
.
Monitoring endosomal trafficking of the g protein-coupled receptor somatostatin receptor 3
.
Methods Enzymol
.
2014
;
534
:
261
80
.
44.
Lehmann
A
,
Kliewer
A
,
Günther
T
,
Nagel
F
,
Schulz
S
.
Identification of phosphorylation sites regulating sst3 somatostatin receptor trafficking
.
Mol Endocrinol
.
2016
;
30
(
6
):
645
59
.
45.
Lee
M
,
Lupp
A
,
Mendoza
N
,
Martin
N
,
Beschorner
R
,
Honegger
J
, et al
.
SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary
.
Endocr Relat Cancer
.
2015
;
22
(
1
):
111
9
.
46.
Lee
M
,
Marinoni
I
,
Irmler
M
,
Psaras
T
,
Honegger
JB
,
Beschorner
R
, et al
.
Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas
.
Acta Neuropathol
.
2013
;
126
(
1
):
137
50
.
47.
Gulde
S
,
Wiedemann
T
,
Schillmaier
M
,
Valença
I
,
Lupp
A
,
Steiger
K
, et al
.
Gender-specific efficacy revealed by head-to-head comparison of pasireotide and octreotide in a representative in vivo model of nonfunctioning pituitary tumors
.
Cancers
.
2021
;
13
(
12
):
3097
.
48.
Senrung
A
,
Lalwani
S
,
Janjua
D
,
Tripathi
T
,
Kaur
J
,
Ghuratia
N
, et al
.
3D tumor spheroids: morphological alterations a yardstick to anti-cancer drug response
.
In vitro models
.
2023
;
2
(
6
):
219
48
.
49.
Tirosh
A
,
Stemmer
SM
,
Solomonov
E
,
Elnekave
E
,
Saeger
W
,
Ravkin
Y
, et al
.
Pasireotide for malignant insulinoma
.
Hormones
.
2016
;
15
(
2
):
271
6
.
50.
Brown
E
,
Watkin
D
,
Evans
J
,
Yip
V
,
Cuthbertson
DJ
.
Multidisciplinary management of refractory insulinomas
.
Clin Endocrinol
.
2018
;
88
(
5
):
615
24
.
51.
Oziel-Taieb
S
,
Maniry-Quellier
J
,
Chanez
B
,
Poizat
F
,
Ewald
J
,
Niccoli
P
.
Pasireotide for refractory hypoglycemia in malignant insulinoma: case report and review of the literature
.
Front Endocrinol
.
2022
;
13
:
860614
.
52.
Maffezzoni
F
,
Formenti
AM
,
Mazziotti
G
,
Frara
S
,
Giustina
A
.
Current and future medical treatments for patients with acromegaly
.
Expert Opin Pharmacother
.
2016
;
17
(
12
):
1631
42
.
53.
Kunz
PL
,
Graham
NT
,
Catalano
PJ
,
Nimeiri
HS
,
Fisher
GA
,
Longacre
TA
, et al
.
Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)
.
J Clin Oncol
.
2023
;
41
(
7
):
1359
69
.
54.
Elston
MS
,
Meyer-Rochow
GY
,
Conaglen
HM
,
Clarkson
A
,
Clifton-Bligh
RJ
,
Conaglen
JV
, et al
.
Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas
.
Hum Pathol
.
2015
;
46
(
3
):
390
6
.
55.
Kanakis
G
,
Grimelius
L
,
Spathis
A
,
Tringidou
R
,
Rassidakis
GZ
,
Öberg
K
, et al
.
Expression of somatostatin receptors 1–5 and dopamine receptor 2 in lung carcinoids: implications for a therapeutic role
.
Neuroendocrinology
.
2015
;
101
(
3
):
211
22
.
56.
Frati
A
,
Rouzier
R
,
Lesieur
B
,
Werkoff
G
,
Antoine
M
,
Rodenas
A
, et al
.
Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer
.
Anticancer Res
.
2014
;
34
(
8
):
3997
4003
.
57.
Oron-Herman
M
,
Kirmayer
D
,
Lupp
A
,
Schulz
S
,
Kostenich
G
,
Afargan
M
.
Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach
.
Sci Rep
.
2023
;
13
(
1
):
20857
.
You do not currently have access to this content.